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The Hippo-YAP signaling pathway is a critical regulator of proliferation, apoptosis, and cell
fate. The main downstream effector of this pathway, YAP, has been shown to be mis-
regulated in human cancer and has emerged as an attractive target for therapeutics. A
significant insufficiency in our understanding of the pathway is the identity of transcriptional
targets of YAP that drive its potent growth phenotypes. Here, using liver cancer as a model,
we identify NUAK2 as an essential mediator of YAP-driven hepatomegaly and tumorigenesis
in vivo. By evaluating several human cancer cell lines we determine that NUAK2 is selectively
required for YAP-driven growth. Mechanistically, we found that NUAK2 participates in a
feedback loop to maximize YAP activity via promotion of actin polymerization and myosin
activity. Additionally, pharmacological inactivation of NUAK2 suppresses YAP-dependent
cancer cell proliferation and liver overgrowth. Importantly, our work here identifies a specific,
potent, and actionable target for YAP-driven malignancies.
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Uncontrolled cell growth is a hallmark of cancer, oftendriven by mutations in pathways that control cell pro-liferation and survival. The Hippo-YAP network is one
such pathway, which has also been implicated in the control of
developmental transitions, organ size, regeneration, and cell
fate1–5. The transcriptional co-activators YAP and the highly
similar protein TAZ are the major downstream effectors of this
pathway. YAP/TAZ are negatively regulated by a core cascade of
proteins, including NF2, LATS1/2, and MST1/2. YAP/TAZ are
directly phosphorylated by LATS1/2, which leads to their cyto-
solic retention and subsequent proteasomal degradation6–8. In the
absence of Hippo pathway engagement, YAP/TAZ translocate
into the nucleus and through interactions with the TEAD family
of transcription factors, activate genetic programs involved in
proliferation and survival9,10. Important inputs into the Hippo
signaling cascade, include cell density, cell polarity, and cell
tension, which signals to YAP/TAZ via the cytoskeleton11–13.
Tight control of YAP activity is crucial for normal tissue growth
and homeostasis. Experimental activation of YAP via genetic
means leads to massive tissue overgrowth, stem cell expansion,
and tumorigenesis1,14. Furthermore, YAP is required for the
growth of multiple epithelial and nonepithelia tumors in mouse
models15–19. While the frequency of mutations for components of
the Hippo pathway is rare in most tumor types, a myriad of
clinical evidence has shown that YAP is found overexpressed, and/
or highly activated in multiple types of malignancies20,21, and its
nuclear localization is positively correlated with poor prognosis in
many cancers22–24. Consequently, the Hippo-YAP pathway has
emerged as an attractive and novel therapeutic target for oncology.
However, a major caveat in developing molecules that antagonize
YAP is the lack of traditional druggable molecules in the pathway.
Current known kinases of the Hippo signaling pathway are growth
suppressive, and therefore unsuitable as cancer targets. And while
some progress has been made in developing molecules that could
inhibit the YAP/TEAD interaction25, the intrinsic nature of
inhibiting protein–protein interfaces makes this approach spe-
cially challenging. Thus, the identification of traditional drug
targets, i.e., enzymes, in the pathway would represent an impor-
tant step forward.
Extensive work has been done to profile the genetic program
regulated by YAP in multiple cell types. While several datasets
have been assembled describing direct targets of YAP in various
datasets, the significance of these targets to the function of YAP is
unclear, especially in context of cancer. The best well studied
downstream targets, for instance, (i.e., CTGF, CYR61, and
AMOTL2) are not considered to have an oncogenic role. While
other YAP-targets have been shown to have some proliferative
effect in cell lines, the relevance and potency of these to suppress
YAP phenotypes in vivo has not been demonstrated9,26–29. The
identification of bona fide effectors downstream of YAP would
not only provide a deeper understanding of the oncogenic
mechanisms of this pathway, but could also novel actionable
entry-points for YAP-driven cancer.
On the basis of the remarkable effects of YAP on liver growth
and the general dependency of liver tumors on YAP activity1,14,19,
here we use the liver as a model system to elucidate important
drivers of YAP function. By overlapping with the genome-wide
chromatin occupancy analyses and gene expression profiling
datasets, we identified the kinase NUAK2, as a critical mediator of
YAP-driven growth. Furthermore, using both genetic and phar-
maceutical inhibition of NUAK2, we provide evidence for its
requirement in YAP-driven proliferation and tumorigenesis.
Thus, NUAK2 serves as a central player in the remarkable effects
of YAP on liver growth, the general dependency of liver tumors
on YAP activity, and it represents an actionable entity within the
pathway that could be amenable to target Hippo/YAP signaling.
Results
Identification of YAP target genes. YAP overexpression in liver
leads to hepatomegaly and liver tumorigenesis1,14. To function-
ally identify critical and direct YAP-targets mediating this
response, we performed chromatin immunoprecipitation fol-
lowed by sequencing (ChIP-Seq) for TEAD4 as a surrogate of
YAP binding after inducible expression of YAP S127A in murine
hepatocytes. The S127A mutation abolishes one of several
phosphorylation sites of LATS1/2 and displays a partial increase
in nuclear localization30. As shown previously in human liver
cancer cell lines, we find that TEAD4 is predominantly bound to
distal regulatory elements, a large fraction of which overlap with
H3K27ac active enhancer marks31 (Fig. 1a). We next assigned the
corresponding target genes to the TEAD4 bound regulatory ele-
ments and assessed their relative expression in the livers of
induced TetO-YAP-S127A mice (Fig. 1b). This identified bound
and regulated genes were then cross-referenced to data obtained
from YAP ChIP-Seq and RNA-seq experiments in HuCCT-1
human cholangiocarcinoma cells31 to select a list of 14 direct and
conserved YAP transcriptional targets (Supplementary Table 1).
Nuak2 is a direct target of YAP. Considering the lack of tradi-
tional drug targets in the Hippo pathway, we decided to focus on
identifying kinases, which were potentially actionable targets of
pharmacological inactivation. Of the 14 targets identified only
one matched this criteria, NUAK2.
NUAK2, also known as sucrose nonfermenting (SNF1)-like
kinase (SNARK), belongs to the AMPK protein kinase family32.
NUAK2 has been mostly implicated in human cancer develop-
ment by amplifications in human melanoma, although copy
number gains of 1q32 are found in other epithelial malignan-
cies33–35. However, other data suggest that NUAK2 might have
tumor suppressive roles in the context of a colorectal cancer
model36. Thus, our understanding of the role of NUAK2 in
cancer is still quite limited.
We first examined in more detail the regulation of NUAK2
expression by YAP. Analysis of ChIP-seq datasets revealed robust
binding of YAP and TEAD to sequences downstream of
NUAK231,37,38, in human cholangiocarcinoma (Fig. 1c),
mesothelioma (Fig. 1d), breast adenocarcinoma, glioblastoma,
and fetal lung cell lines (Supplementary Fig. 1a). Further
inspection of individual peaks revealed that the YAP occupancy
sites co-localized with enhancer elements, as defined by typical
enhancer-associated histone posttranslational modifications
(H3K27ac+) (Fig. 1c, d). These enhancers were classified as
super-enhancers in human cholangiocarcinoma and mesothe-
lioma cell lines, arguing for the importance of NUAK2 in these
cancers (Fig. 1f). Consistently, YAP and TEAD4 also co-occupied
an enhancer downstream of mouse Nuak2 in the liver of TetO-
YAP S127A mice (Fig. 1e). Furthermore, we validated that acute
YAP overexpression led to the up-regulation of NUAK2 mRNA
and protein (Fig. 1g, h). Conversely, YAP or YAP/TAZ knock-
down in HuCCT-1 cells nearly abolished the expression of
NUAK2 mRNA (Fig. 1i). We also identified two putative TEAD-
responsive elements (TREs) based on consensus TEAD-binding
sequences in the YAP/TEAD-defined NUAK2 enhancers (Sup-
plementary Fig. 1b). Mutation of one of these (TRE1), but not the
other, abolished YAP-driven transcriptional induction of NUAK2
enhancer activity (Supplementary Fig. 1b). Recent work has also
identified Nuak2 as Yap transcriptional target in embryonic
lungs39. Together, our results indicate that YAP directly regulates
NUAK2 transcription through TEAD-binding to the NUAK2
super enhancer.
To extend our findings of YAP-mediated NUAK2 induction
to human cancer, we analyzed the expression profiles of YAP
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07394-5
2 NATURE COMMUNICATIONS |          (2018) 9:4834 | DOI: 10.1038/s41467-018-07394-5 | www.nature.com/naturecommunications
and NUAK2 and the correlation of YAP and NUAK2 in
hepatocellular carcinoma (HCC) through bioinformatics ana-
lyses. In support of our model, we found that NUAK2
expression levels are significantly up-regulated in a large cohort
of HCC samples (Fig. 1j). Importantly, the level of NUAK2
transcript was significantly and positively correlated with YAP
mRNA abundance (Fig. 1k). Collectively, these findings lend
strong support to the YAP-driven NUAK2 misregulation in
human HCC.
NUAK2 is critical for YAP-driven liver growth and cancer. To
further demonstrate a role for NUAK2 downstream of YAP, we
generated recombinant AAV2/8 viruses expressing two Nuak2 or
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Fig. 1 NUAK2 is a direct target of YAP. a Heatmap representing TEAD4/H3K27ac ChIP-seq signal in a window of ±3 Kb from the center of TEAD4 peaks.
Clustering results from the K-means method. b Venn diagram displays overlapping genes from 4 different datasets to identify 14 accordant YAP
downstream genes. The datasets include: (1) a TEAD4 ChIP-seq from the liver of induced TetO-YAP mice, (2) a YAP ChIP-seq, from human
cholangiocellular carcinoma cell line, HuCCT-1, (3) an RNA-seq from HuCCT-1 cells upon YAP/TAZ silencing, and (4) an RNA-seq from the liver of induced
TetO-YAP mice. c, d Genomic tracks display ChIP-seq data for the indicated antibodies around the NUAK2 gene in HuCCT-1 (c) and MSTO-211H cells (d).
e Genomic tracks display ChIP-seq data for the indicated antibodies around the Nuak2 gene in primary hepatocytes of TetO-YAP S127A mice placed on
Dox for 4 days. f Hockey-stick plot representing H3K27ac signal across enhancer regions for all enhancers in HuCCT-1 (left panel) and MSTO221H (right
panel) cells. Super enhancers are labeled by dark blue, with the super enhancer of Nuak2 marked. g qPCR analysis of NUAK2 expression in HuCCT-1 and
H69 cells stably expressing Dox-inducible YAP-S127A. Data are presented as mean ± SD; n= 3. The two-tailed, Student’s t test was used to compare
between two groups and expressed as P values. *P < 0.05, **P < 0.01, ***P < 0.001. h YAP overexpression promotes NUAK2 expression. Dox-inducible
HuCCT-1 and H69 cells treated with or without Dox for 24 h were assayed by Western blot for the indicated antibodies. i qPCR analysis of NUAK2
expression in HuCCT-1 cells transfected with indicated siRNA for 72 h (left panel). Right panel showing the knockdown efficiency of YAP and TAZ. Data are
presented as mean ± SD; n= 3. The two-tailed, Student’s t test was used to compare between two groups and expressed as P values. *P < 0.05, **P < 0.01,
***P < 0.001. j Expression profiles of NUAK2 and YAP in HCC patient specimens and their adjacent normal specimens. n= 233 pairs, P= 6.84E−15 (paired
Wilcoxon test). k Spearman correlation analysis of NUAK2 expression with YAP expression in HCC patient samples. n= 247, Rs= 0.34, P= 3.2E−08
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hYAP targeting sgRNAs in addition to Cre recombinase (Fig. 2a).
High titer administration of the Nuak2 sgRNA virus to TetO-
YAP:Cas9 mice40 resulted in a Nuak2 knockout efficiency of
approximately 70% from analysis of bulk liver DNA (Supple-
mentary Fig. 2b). Considering there are still 30% of non-
parenchymal cell types in the liver, which are not infected by the
AAV2/8, our data actually underestimate the efficiency of Nuak2
deletion in hepatocytes, suggesting an almost complete knockout
efficiency. We then administrated this AAV virus into adult mice
bearing a Cre-dependent SpCas9-GFP transgene40, and a Cre-
dependent, Doxycycline (Dox)-inducible human YAP-S127A
allele1,41 (Fig. 2a) (to be referred as TetO-YAP:Cas9 hereafter).
When a control AAV-Cre virus was injected into TetO-YAP:Cas9
mice, Dox induction led to massive and rapid hepatomegaly, as
reported before1,14. Consistent with our previous data, YAP
overexpressing livers exhibited higher NUAK2 expression at the
mRNA and protein levels (Fig. 2d, e and Supplementary Fig. 2c).
Strikingly, TetO-YAP:Cas9 mice infected with AAV-Cre-sgRNA-
Nuak2 demonstrated a substantial and highly significant reduc-
tion in liver overgrowth and hepatocyte proliferation (Fig. 2b, c).
To rule out nonspecific effects of the guide strand targeting,
AAV-Cre-nontargeting sgRNAs was also included as control.
Indeed, it displayed similar hepatomegaly phenotype as AAV-
Cre. Most importantly, AAV-Cre-sgRNA-Nuak2 demonstrated a
reduction in liver overgrowth (Supplementary Fig. 2a). The
protein Myosin phosphatase target subunit (MYPT1) is currently
the only validated substrate for NUAK2 kinase42,43. As predicted
from our model, a significant increase in MYPT1 phosphoryla-
tion at serine 445, which is characterized as a NUAK2 phos-
phorylation site, was found in the livers of TetO-YAP:Cas9 mice
infected with the control Cre virus. Phosphorylation of this
substrate was abolished in the context of Nuak2 AAV-mediated
knockout (Fig. 2d).
In addition to the short-term effects of Nuak2 knockout in
YAP-mediated overgrowth, we assessed the role of NUAK2 in a
longer-term model of YAP-activation that leads to liver cancer. A
mixed HCC/ICC pathology is generated by the expression of
YAP-S127A for three months in a very small number of
hepatocytes, achieved by the administration of a very low dose
of AAV-Cre (Supplementary Fig. 2d). Strikingly, in this model,
genetic ablation of Nuak2 significantly suppressed the overall size,
grade, and number of tumors formed (Fig. 2f, g). Taken together,
our data strongly corroborate the essential role of NUAK2 in
YAP-mediated hepatomegaly and tumorigenesis.
Loss of NUAK2 impairs growth in YAP-high liver cancer cells.
We next examined the requirement for NUAK2 in the pro-
liferation of human cancer cells. Indeed, either NUAK2 knockout
by multiple sgRNAs or knockdown by shRNAs significantly
suppressed proliferation of HuCCT-1 cells (Fig. 3a and Supple-
mentary Fig. 3a, b). Importantly, growth inhibition in this context
could be rescued by expression of a NUAK2 wild-type construct,
but not by a kinase-dead mutant (Fig. 3b and Supplementary
Fig. 3c), indicating the kinase dependent role of NUAK2 in
controlling cell growth in vitro. Considering the strong functional
relationship between YAP and NUAK2, we assessed whether liver
cancer cell lines would show a selective response towards NUAK2
inhibition depending upon YAP/TAZ activity. We first selected
several liver cancer cell lines with high- or low-YAP activity by
determining YAP expression level (Fig. 3c), the activity of a
TEAD/YAP transcriptional reporter44 (Supplementary Fig. 3d),
and the expression signature of YAP downstream targets (Sup-
plementary Fig. 3e). From these data we cataloged HuCCT-1 and
SNU475 cells as “YAP-high”, whereas we considered HepG2 and
SNU398 as having “YAP-low” activity. Furthermore, MYPT1, the
substrate of NUAK2, was highly phosphorylated at S445 in YAP-
high cells, but not in cells with low YAP activity (Fig. 3c). As
predicted, depletion of YAP/TAZ significantly inhibited the
growth of YAP-high cells, while only negligible effects were
observed in YAP-low cells (Fig. 3d and Supplementary Fig. 3f, g).
Strikingly, YAP-high cells displayed a much higher sensitivity to
NUAK2 knockdown than YAP-low cells (Fig. 3d and Supple-
mentary Fig. 3h). In addition to using YAP-high and -low cells,
we also utilized the cell lines with Hippo pathway mutations to
demonstrate the role of NUAK2 on YAP-driven cell growth. As
shown in Fig. 3e, the breast cancer cell line MDA-MB-231 and
mesothelioma cell line NCI-H2052, cell lines with a known loss of
NF2 expression, an upstream negative regulator of YAP, dis-
played higher phosphorylation of YAP on S127, compared to
their counterpart wild-type NF2 cell lines. In line with our pre-
vious data, NUAK2 depletion significantly reduced the cell pro-
liferation of the NF2 lost cell lines, while only negligible effects
were observed in wild-type cells (Fig. 3f). Taken together, these
data highlight NUAK2 inhibition as a potential selective depen-
dency for YAP-driven malignancies.
YAP-mediated NUAK2 induction auto-amplifies YAP activity.
Several previous reports have demonstrated that the actomyosin
cytoskeleton regulates YAP activity11,45–47. As NUAK2 phos-
phorylates MYPT1 on S445, a regulatory subunit of the myosin
light chain phosphatase (MLCP), it thereby inhibits phosphatase
activity of MLCP to increase MLC phosphorylation with sub-
sequent triggering of the assembly of actin fibers and creation of
actomyosin tension48–51. Therefore, we hypothesized that YAP-
mediated NUAK2 induction could form a double positive feed-
back loop to auto-amplify YAP activity through positively reg-
ulating actomyosin tension. Consistent with this hypothesis,
knockdown of NUAK2 reduced MYPT1 phosphorylation on S445
and promoted MLC dephosphorylation in vitro (Fig. 4a, b),
which resulted in the disassembly of actin fibers (Fig. 4c).
Depletion of NUAK2 led to the increased cytoplasmic accumu-
lation of YAP (Fig. 4b–e) and the subsequent reduction of YAP
transcriptional activity, as assayed by the mRNA expression of
well-known YAP target genes, such as CTGF, CYR61, AMOTL2,
and ANKRD1 (Fig. 4f and Supplementary Fig. 4a).
Mechanistically, NUAK2 depletion also increased YAP cyto-
plasmic retention through moderately inducing YAP phosphor-
ylation and 14-3-3 binding (Supplementary Fig. 4b, c), which is a
well-known mechanism for YAP cytosolic retention30. However,
whether NUAK2-mediated YAP translocation depends on the
Hippo pathway still need to be further confirmed. More
importantly, depletion of MYPT1 in the NUAK2-knockdown
cells partially rescued not only cell growth but also YAP
transcriptional activity (Supplementary Fig. 4d–f), indicating the
involvement of MYPT1 in NUAK2 depletion-induced effects on
cell growth inhibition and reduction of YAP activity.
To further examine the physiological YAP-NUAK2-MYPT1
axis in vivo, we also analyzed this signaling cascade in TetO-YAP:
Cas9 mouse livers. YAP induction promoted NUAK2 expression
with a consequential drastic increase in MLC phosphorylation,
whereas Cas9-mediated viral Nuak2 knockout attenuated this
phenotype (Fig. 4g). Accordingly, NUAK2-depleted livers
demonstrated reduced junctional actin fibers (Fig. 4h), which in
turn resulted in less robust YAP nuclear localization (Fig. 4i) and
significantly dampened transcriptional activity (Fig. 4j and
Supplementary Fig. 4g).
If NUAK2 indeed participates in cell growth control via the
regulation of YAP subcellular localization, we reasoned that
forced translocation of YAP to the nucleus should rescue the
phenotype of NUAK2 depletion. We tested this by stably
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Fig. 2 NUAK2 plays a critical role in YAP-driven hepatomegaly and tumorigenesis. a Top, schematic of AAVs utilized containing two sgRNAs targeting
either Nuak2 or transgenic YAP. Middle, transgenic mice bearing these three alleles were used for CRISPR/Cas9-mediated knockout of Nuak2 in a YAP
overexpression model. Bottom, experimental flow chart depicting protocol for YAP-mediated acute liver overgrowth. b Gross morphology of the livers of
TetO-YAP:Cas9 transgenic mice infected with indicated AAV virus and placed on Dox for 2 weeks. Liver/body weight ratio of mice mentioned before was
plotted. Data are presented as mean ± SD; n= 4 or 6. The two-tailed, Student’s t test was used to compare between two groups and expressed as P values.
*P < 0.05, **P < 0.01, ***P < 0.001. c Representative Ki67 staining of liver sections as in (b) and quantification of Ki67 positive cells were shown. Data are
presented as mean ± SD; n= 4 mice per group, 5 or 6 high power field (HPF) per animal. The two-tailed, Student’s t test was used to compare between two
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n= 3 animals. The two-tailed, Student’s t test was used to compare between two groups and expressed as P values. *P < 0.05, **P < 0.01, ***P < 0.001.
g Hematoxylin and eosin (H&E) and IHC analysis of liver tumor sections as in (f). Bar, 100 μm
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07394-5 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:4834 | DOI: 10.1038/s41467-018-07394-5 |www.nature.com/naturecommunications 5
expressing a YAP-S127A construct carrying an ectopic nuclear
localization signal (NLS), which should lead to constitutive
nuclear translocation independent of cytoskeletal regulation.
While the S127A mutation can also have an effect on nuclear
localization, by itself it is not sufficient to confer full nuclear
localization given that other Ser residues are also modified by
LATS, and it is still subject to regulation by the cytoskeleton11,30.
As predicted, the NLS-YAP-S127A mutant was largely accumu-
lated in the nucleus, even in the absence of NUAK2, in contrast to
the mostly cytoplasmatic localization of YAP-S127A (Supple-
mentary Fig. 4h). Remarkably, NLS-YAP-S127A overexpression,
but not YAP-S127A, partly restored growth inhibition caused by
NUAK2 knockdown (Fig. 4k). Collectively, these data demon-
strate that YAP-driven NUAK2 activity influences the
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actomyosin cytoskeleton, which in turn forms a double positive
feedback loop to maximize YAP activity.
HTH-02-006 as a semispecific NUAK2 inhibitor. Considering
our observations suggesting that NUAK2 is critical for YAP-
driven cell proliferation and its oncogenic phenotypes, the
development of NUAK2 kinase inhibitors represents an attractive
avenue for intervention in YAP-driven cancers. Here, we
employed a novel semispecific inhibitor of NUAK2, HTH-02-006
(NUAK2 IC50= 126 nM), optimized from WZ400352 with
improved selectivity to study the pharmacologic consequences of
NUAK2 inhibition (Fig. 5a, b and Supplementary Fig. 5a).
Indeed, HTH-02-006 treatment reduced levels of phosphorylated
MYPT1 in HuCCT-1 cells indicating its activity on NUAK2 and/
or NUAK1, which can also phosphorylate MYPT143 (Fig. 5c). To
examine the selectivity of HTH-02-006, we treated YAP-high and
-low cell lines with increasing concentration of HTH-02-006. We
find that YAP-high cell lines exhibit a notably higher sensitivity to
the compound (Fig. 5d). To further demonstrate the specificity of
HTH-02-006, we performed a protein sequence alignment of
NUAK1 and NUAK2 and identified the A236 residue of NUAK2
that is conserved with the corresponding A195 residue of
NUAK1, which is the binding site to WZ400352 (Supplementary
Fig 5b). Based on the structural similarity of HTH-02-006 with its
proto-type inhibitor WZ4003, we expected that the A236 site of
NUAK2 would be crucial for successful binding of HTH-02-006.
Indeed, bi-allelic knock-in NUAK2A236T/A236T cells generated by
CRISPR gene-editing conferred partial resistance to HTH-02-006
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induced inhibition of MYPT1 phosphorylation, while MYPT1
phosphorylation was robustly downregulated in WT cells
(Fig. 5e), suggesting A236T was a drug resistant mutant. In line
with this notion, NUAK2 A236T cells were more resistant to
HTH-02-006 induced cell growth inhibition, as compared to its
counterpart WT cells (Fig. 5f), indicating that the effect of HTH-
02-006 treatment is at least in part through inhibition of NUAK2
activity. Because HTH-02-006 does not only inhibit NUAK2 but
also NUAK1 activity, we also tested whether NUAK1 is required
for cell growth of HuCCT-1 cells. Compared to NUAK2, NUAK1
depletion exhibited negligible effects at similar knockdown effi-
ciency, suggesting that the effect of HTH-02-006 is likely medi-
ated through NUAK2, at least in this cellular context
(Supplementary Fig. 5c).
NUAK2 inhibition reduces YAP-driven liver growth and can-
cer. To investigate the efficacy of the NUAK2 inhibitors in vivo,
high-dose AAV-Cre receiving TetO-YAP S127A mice were
injected intraperitoneally with HTH-02-006 (10 mg/kg) twice
daily. At this dose, HTH-02-006 did not exert overt toxicity, as
there was no evidence of body weight loss (Supplementary
Fig. 5d). During the treatment period, mice were also adminis-
tered Dox to activate YAP expression and to induce hepatocyte
proliferation and consequent hepatomegaly. Compared with
vehicle control, mice subjected to HTH-02-006 treatment
exhibited potent suppression of YAP-induced liver overgrowth
and a decreased number of proliferating hepatocytes (Fig. 5g).
Furthermore, analysis of liver tissues also demonstrated drama-
tically decreased phosphorylation of MYPT1 at S445 (Fig. 5h).
Finally, we assessed the consequences of pharmacological
NUAK2 in YAP-driven tumorigenesis. For this, we subcuta-
neously transplanted Dox-inducible YAP overexpressing
HuCCT-1 cells into nude mice. Even though these cells exhibit
nuclear YAP endogenously, exogenous expression of YAP
permits faster growth of xenografts. When such tumors reached
a volume of ~100 mm3, mice were then treated with vehicle or
HTH-02-006 (10 mg/kg) for 30 days. Continuous treatment of
inhibitors did not affect body weight (Supplementary Fig. 5e),
suggesting HTH-02-006 is well tolerated in nude mice. Compared
to vehicle control, the growth rates of the tumors were
significantly attenuated in HTH-02-006-treated mice (Fig. 5i
and Supplementary Fig. 5e), indicating the antitumor activity of
HTH-02-006. Together with our genetic data, our results strongly
suggest that inhibition of NUAK2 kinase activity potently
suppresses YAP-driven hepatomegaly and tumor growth.
Discussion
The Hippo-YAP signaling pathway is thought to be a major
contributor to tumorigenesis. Extensive data in animal models
and clinical evidence support the idea that YAP/TAZ represent
attractive therapeutic targets in cancer18. While some progress
has been made in attempting to inhibit the YAP and TEAD
interaction25, as well as the stability of these molecules, because of
the inherent limitations to such approaches there is still no spe-
cific and potent YAP/TAZ antagonist. Our data suggest an
alternative way of targeting YAP, at least in the liver, which is by
chemical inhibition of the NUAK2 kinase. Here, we provide
genetic and chemical evidence that such interventions could
represent a selective vulnerability of YAP-driven tumors.
NUAK2 is frequently amplified in a range of human cancers,
forming part of the 1q32 amplicon common in melanoma, glio-
blastoma and other cancers33,34,53. Co-amplification of other
oncogenes such as MDMX and the RAS-pathway effector ELK4
have, however, complicated the interpretation of the relevance of
chromosomal gains containing NUAK254. Further, heterozygous
knockout NUAK2 mice are sensitized to azoxymethane-induced
colonic tumor formation36. Our data here are consistent with a
clear growth-promoting function of NUAK2, at least in the
hepatic context. Our work largely implicates myosin filaments
and the actin cytoskeleton in the growth-promoting function of
NUAK2. However, it is important to note that very little is known
about the other targets of this kinase, and it is likely that other
substrates might also play an oncogenic role downstream of
NUAK2. For instance, it has been reported that mTOR activation
and CDK2 induction are associated with NUAK2 expres-
sion34,55,56 though the underlying mechanisms remain unclear.
Clearly, elucidation of the full set of NUAK2 substrates will clarify
this issue. Additionally, several inputs including nutrient and
oxidative stress have been shown to act upstream of NUAK257,58.
To what extent these can impinge upon YAP activity and growth
remain to be determined.
Targeting the Hippo pathway has become an intriguing avenue
for cancer therapeutics. One major limitation to move this for-
ward has been the lack for traditionally druggable molecules in
the pathway. While inhibitors for Mst1/2 kinases have been
reported59, these inhibitors are likely to be useful in a pro-
regenerative context, but not in a cancer setting, given the known
growth suppressive function of Mst1/2. Interfering with the
interactions of YAP with TEAD or other regulatory factors is
another approach, although the lack of enzymatic pockets in these
proteins will require the development of antagonists of
protein–protein interfaces, an strategy that has been historically
challenging20. Our data here provide multiple lines of evidence
that inhibitors of the kinase activity of NUAK2 represent a novel
approach to modulate YAP function in vivo. Moreover, our data
suggest that NUAK2 inhibition might represent a selective vul-
nerability of cancer cells with high YAP activity. It is unclear at
this point, whether this finding is limited to liver cancer, or
whether it could be applicable to other malignancies. Addition-
ally, it will be important to identify particular cancer genotypes
that would correlate with sensitivity to NUAK2 depletion. In any
case, the novel compound described in this report, could be the
basis for the development of more specific and potent inhibitors.
In addition to its aberrant role in tumorigenesis, the Hippo-
YAP signaling cascade is physiologically involved in the control
of many basic biological functions. Therefore, the dynamics of
YAP/TAZ activity have to be tightly controlled to ensure the
proper physiological functions. Several negative feedback reg-
ulatory mechanisms control YAP activity to prevent over-
activation60–62. In this study, we elucidate a mechanism by
which YAP-mediated NUAK2 induction amplified YAP activity
via the cytoskeleton. Together with other positive regulatory
mechanisms63, YAP activity is able to be amplified rapidly and
robustly to ensure a timely adjustment during acute conditions,
like tissue injury, thereby maintaining tissue homeostasis. How-
ever, tumor cells can also hijack these pathways to drive uncon-
trolled cell growth. It might also explain the dominant YAP-
activation phenotypes in many cancer types without genetic
aberrations of the pathway.
Methods
Cell culture and establishment of stable cell lines. All cell lines were obtained
from American Type Cell Collection (ATCC, USA). HuCCT-1, SNU475, SNU398,
MDA-MB-231, MDA-MB-468, and NCI-H2052 cells were cultured in RPMI
containing 10% FBS, 1× Hepes, 1× L-glutamine. HepG2 and 293T cells were cul-
tured in Dulbecco modified Eagle’s medium (DMEM) containing 10% FBS. H69
were maintained in DMEM: DMEM/F12 containing 10%FBS and supplemented
with Adenine, Insulin, Epinephrine, T3-T, EGF and hydrocortisone as previously
reported64. MET-5A were maintained in Medium 199 containing 10%FBS and
supplemented with HEPES, insulin, EGF, trace elements B and hydrocortisone.
HuCCT-1 and H69 TetO-YAP stable cells were generated by lentiviral transduc-
tion of a plasmid expressing M2-rtTA construct and a pNL-TRE-YAPS127A
plasmid. HuCCT-1 NLS-YAP S127A and YAP-S127A were generated by lentiviral
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transduction. NUAK2 shRNAs were obtained from GE Dharmacon (RHS4533-
EG81788). siRNAs were obtained from Ambion (YAP s20367, TAZ s24787,
NUAK2 s37779, and MYPT1 s9235) and Sigma (NUAK1 SASI_Hs01_00188391).
All plasmid transfections were performed with Lipofectamine 3000 and siRNA
transfections were performed with Lipofectamine RNAiMAX according to the
manufacturer’s recommendations.
Plasmids. NUAK2 cDNA was cloned to pRK5-Flag and NUAK2 T252E (kinase-
dead) and G9A mutants were generated by site-directed mutagenesis.
Immunofluorescence. Cells were fixed with 4% paraformaldehyde/phosphate-
buffered saline (PBS) for 10 min at room temperature, followed by three washes in
PBS. Cells were permeabilized in 0.01% Triton/PBS for 1 min, followed by three
washes in 0.01% Tween/PBS and then blocked with PBS supplemented with 10%
donkey serum for 1 h. Cells were incubated with primary antibody (YAP
(Cat#14071, 1:200, Cell signaling), pMLC (Cat#3671, 1:100, Cell signaling), actin
(Cat#A5316, 1:200, Sigma) and Flag (Cat#F3165, 1:400, Sigma)) in blocking buffer
for overnight. After three washes in 0.1% Tween PBS, cells were incubated in
secondary antibody and 1 μg/ml DAPI for 1 h at room temperature. Cells were then
washed, mounted and examined with a confocal microscope (Zeiss LSM 700 Laser
Scanning Confocal), equipped with a 25× or 40× oil objective lens or epimicro-
scope (Zeiss Axio Observer Z1).
Immunohistochemistry. Tissue was fixed in 4% paraformaldehyde (PFA) for 48 h
and then embedded in paraffin for sectioning. Tissue sections measuring 5 µm were
deparaffinized and rehydrated followed by antigen retrieval using low-pH Antigen
Unmasking Solution (Vector Labs, Burlingame, CA). Quenching of endogenous
peroxidase (0.3% H2O2) and protein block (10% Donkey serum) was performed
prior to overnight primary antibody incubation at 4 °C (GFP (Cat#ab6673, 1:1000,
Abcam), YAP (Cat#14071, 1:400, Cell Signaling), Ki67 (Cat#GTX166667, 1:200,
GeneTex), Sox9 (Cat#AB5535, 1:200, Millipore), actin (Cat#A5316, 1:100, Sigma)).
Sections were washed and Vectastain Elite ABC kit and secondary antibody
(Vector Labs) were used to detect primary antibody binding. Slides were developed
using the Vectastain Elite kit used as directed by the manufacturer. Counterstaining
was done with haematoxylin and samples were washed, dehydrated, and mounted
with Vectamount (Vector Labs #H-5000).
Immunoblotting. Cells and tissue were collected, and processed for western blot-
ting by solubilizing extracts in radioimmunoprecipitation assay (RIPA) buffer with
protease inhibitor cocktail (Roche #04693159001) and phosSTOP (Roche, #
04906837001)). Protein lysates were resolved by polyacrylamide gel electrophoresis
(PAGE) under reducing conditions (4–12% sodium dodecyl sulfate–PAGE
Bis–Tris gels; MOPS buffer system; Invitrogen; NuPAGE-MOPS system). The gels
were blotted onto nitrocellulose or PVDF membranes and blocked in either 5%
milk or 1% bovine serum albumin and followed by primary antibody incubation
for overnight (NUAK2 (Cat#sc-374348, 1:100, Santa Cruz), YAP (Cat#14071,
1:1000, Cell Signaling), GAPDH (Cat#3683, 1:10000, Cell Signaling), actin
(Cat#A5316, 1:1000, Sigma), pMLC (Cat#3671, 1:1000, Cell Signaling), MLC
(Cat#M4401, 1:1000, Sigma), TAZ (Cat#4883, 1:1000, Cell Signaling), NF2
(Cat#12888, 1:1000, Cell Signaling)). MYPT1 and p-MYPT1 (S445) antibodies
were a kind gift from Dr. Dario Alessi43. After washing with TBST, membranes
were incubated with horseradish peroxidase-conjugated secondary antibodies for 1
h. Blots were washed with TBST and developed with the enhanced chemilumi-
nescence system. Uncropped Western blot images of data shown in Figures can be
found in Supplementary Figure 6.
Immunoprecipitation. HuCCT-1 cells were transfected with the indicated
expression vectors and siRNA. After 72 h transfection, cells were lysed in RIPA
buffer with protease (Roche) and phosphatase (Roche) inhibitor. 1 mg of total
lysates were precleared for 30 min at 4 °C, and then immunoprecipitated with anti-
HA beads (Sigma) overnight at 4 °C. The immunoprecipitates were washed with
RIPA buffer three times.
Cell fractionation. Cells were transfected with indicated siRNA and incubated for
72 h, and then cells were lysed and fractionated into nuclear and cytosolic fraction
using NUCLEI EZ PREP NUCLEI ISOLATION KIT (Sigma) following the man-
ufacturer’s recommendation.
Cell proliferation assay. Cells were transfected with indicated siRNA and incu-
bated for 24 h, and then reseeded into 96-well plates at a density of 2000 cells per
well. At indicated time points, cells were fixed (4% PFA) and stained with crystal
violet. The dye was then extracted by adding 10% acetic acid to each well, and the
absorbance was measured at 600 nm.
In order to test the inhibitors, cells were seeded at a density of 2000 cells per
well in 96-well plates and on the next day treated with HTH-02-006 in the specific
concentrations. After 5 days incubation, cells were fixed and stained with crystal
violet. The dye was then extracted by adding 10% acetic acid to each well, with
absorbance measured at 600 nm.
Mouse models. Animal work was approved by the institutional committee at
Boston Children’s Hospital. Animals were housed in specific pathogen-free facil-
ities at the hospital. Tetracycline-inducible YAP S127A expression mice were
previously described1. Cre-dependent Cas9 mice were obtained from Jackson
Laboratories (Bar Harbour, MA) B6;129-Gt(ROSA)26Sor < tm1(CAG-cas9*,-
EGFP)Fezh > /J. AAV2/8-sgRNA-Cre viruses were generated by Gene Transfer
Vector Core in Harvard Medical School. The specific AAV viruses were injected
retro-orbitally. For TetO-YAP S127A overexpression, 3 days after AAV-Cre
delivery, mice were administered 2 mg/ml doxycycline ad libitum in their water.
To administer inhibitors to mice, HTH-02-006 was dissolved in 5% Dextrose
and 10% DMSO. HTH-02-006 was administered by intraperitoneal route at a dose
of 10 mg/kg for HTH-02-006 twice a day.
For tumor growth in the xenograft model, 8-week-old Nude mice (Jax stock
#00785) were injected s.c. with 5 × 106 HuCCT-1 TetO-YAP S127A cells (n= 4 for
each group) mixed with 100 μl RPMI medium and 100 μl Matrigel (BD). Until
tumor size of Dox administrating mice around 100 mm3, mice were randomly
divided into two groups. Mice were then given vehicle or HTH-02-006 for 30 days.
Luciferase assays. Cells were cotransfected with a pGL3-based reporter construct
and pCMV-Renilla. Luciferase activity in cell lysates was assayed by the Dual
Luciferase Reporter Assay System (Promega). The relative promoter activity was
present as the fold-change in firefly luciferase activity after normalization to the
renilla luciferase activity.
qPCR analysis. Total RNA was extracted from cell pellets using Trizol (Life
Technologies) according to the manufacturer’s instructions. cDNA was synthetized
using iScript Reagents (Biorad). Quantitative polymerase chain reaction (qPCR)
was performed with the One Step plus Sequence Detection System (Applied Bio-
systems) using Fast SYBR green master mix reagent (Applied Biosystems) or
TaqMan-based Real-Time PCR gene expression assays (Applied Biosystems).
Gene expression levels were normalized to a housekeeping gene. qPCR primers
sequences are listed in Supplementary Table 2.
Taqman assays for mouse and human YAP1 (Mm00494240_m1,
Hs00902712_g1), TAZ (Hs00210007_m1), CTGF (Mm01192933_g1,
Hs01026927_g1), Cyr61 (Mm00487499_g1, Hs00964221_g1), AMOTL2
(Mm00502287_m1, Hs01048101_m1), and ANKRD1 (Mm00496512_m1,
Hs00173317_m1) were multiplexed with 18S control assays (Applied Biosystems).
RNA-seq. AAV-Cre was given to TetO-YAP mice retro-orbitally. After 3 days,
mice were administered Dox ad libitum in their cage water. Five days after Dox
administration, hepatocytes were isolated and RNA was purified. RNA-seq libraries
were generated using TruSeq RNA Sample Prep Kit v2 (Illumina) according to
manufacturer’s recommendations. The high-throughput sequencing was carried
out on HiSeq 2000 (Illumina) at the Tufts Genomics Core.
ChIP-seq. Four days after Dox administration, hepatocytes were isolated and
purified from TetO-YAP mice. Hepatocytes were cross-linked in 1% formaldehyde
for 10 min at room temperature after which the reaction was stopped by addition
of 0.125 M glycine. Cells were then lysed in ChIP buffer (100 mM Tris at pH 8.6,
0.3% SDS, 1.7% Triton X-100, and 5 mM EDTA) and the chromatin was sheared
with a Diagenode Bioruptor sonicator UCD-200 to obtain fragments of average size
of 200-500 bp. Suitable amounts of chromatin were incubated with antibodies for
YAP (Cell Signaling #14074), TEAD4 (Abcam ab58310), or H3K27ac antibody
(Abcam ab4729) overnight. Complexes were recovered on Protein-A/G agarose
beads (Pierce) and, after multiple washes, DNA was reverse cross-linked and
purified using the QIAquick PCR purification kit (QIAGEN). Libraries for ChIP-
sequencing were generated by using the NEB Next Ultra DNA Library Prep Kit for
Illumina (NEB) and barcoded using NEB Next Multiplex Oligos for Illumina
(Index Primers Set 1) (NEB) according to the manufacturer’s instructions.
ChIP-Seq data analysis. Fastq files were generated from ChIP-seq of mouse liver
or retrieved from GEO (GSE68296, GSE62275, GSE66083, and GSE61852). ChIP-
Seq data analysis was done using the docker4seq package (https://github.com/
kendomaniac/docker4seq), part of reproducible-bioinformatics project (www.
reproducible-bioinformatics.org). Illumina adapters were removed using skewer65.
Trimmed reads were mapped on the corresponding reference genome (hg38,
mm10) using BWA66. Transcription factors peaks were detected using MACS67
and histone marks using SICER68. The association of peaks to genes was done
using ChIPeakAnno69, Bioconductor package. All analyses were done using the
default parameters set in docker4seq chipseqCounts function. BigWig generation
and normalization was done using bedtool v2.17.070. Enhancers were defined as
regions positive for overlapping H3K27ac and H3K4me1 signals. Super enhancers
were defined as clusters of enhancers within 12.5 kb one from another as default
parameter of the ROSE software, as previously described (Hnisz et al., 2013). Input
constituents used were H3K27Ac+/H3K4Me1+ peaks (putative enhancers) with a
ranking BAM file containing H3K27ac reads, and a control BAM file containing
IgG reads.
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General information for chemical synthesis. Unless otherwise noted, reagents
and solvents were obtained from commercial suppliers and were used without
further purification. 1H NMR spectra were recorded on Bruker A500 (500MHz),
and chemical shifts are reported in parts per million (ppm, δ) downfield from
tetramethylsilane. Coupling constants (J) are reported in Hz. Spin multiplicities are
described as s (singlet), br (broad singlet), d (doublet), t (triplet), q (quartet), and m
(multiplet). Mass spectra were obtained on a Waters Micromass ZQ instrument.
Preparative HPLC was performed on a Waters Sunfire C18 column (19 × 50mm, 5
µM) using a gradient of 15–95% methanol in water containing 0.05% tri-
fluoroacetic acid over 22 min (28 min run time) at a flow rate of 20 mL/min.
Purities of assayed compounds were in all cases greater than 95%, as determined by
reverse-phase HPLC analysis. Details of chemical synthesis and the relevant NMR
spectra are included in Supplementary Method 1.
IC50 determination. HEK-293 cells were transfected with pEBG2T mammalian
constructs expressing N-terminal GST- tagged NUAK2. Active GST–NUAK2 was
purified by glutathione–sepharose52. For peptide kinase assays, each reaction was
performed in duplicate in 96-well plates. Totally, 100 ng of NUAK2 was incubated
in 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 10 mM magnesium acetate, 200 μM
Sakamototide, 0.1 mM [γ-32 P]ATP (450–500 c.p.m./pmol) and the indicated
concentrations of HTH-02-006 dissolved in DMSO for 30 min at 30 °C. Reactions
were terminated by adding 25 mM (final) EDTA to chelate the magnesium. Then,
40 μl of the reaction mix was spotted on to P81 paper and immersed in 50 mM
orthophosphoric acid. Samples were washed three times in 50 mM orthopho-
sphoric acid followed by a single acetone rinse and air drying. The incorporation of
[γ-32 P]ATP into Sakamototide was quantified by Cerenkov counting. The values
were expressed as a percentage of the DMSO control.
CRISPR/Cas9 gene-editing approach. Construction of lenti-CRISPR/Cas9 vec-
tors targeting NUAK2 in human cell lines was performed following the protocol
associated with the backbone vector (Addgene, #52961). The software (http://
crispr.mit.edu/) predicted the following sequences with priority given to sequences
that matched the early coding exons of targeted genes. The guide sequence used are
5′-TGGAGTCGCTGGTTTTCGCG-3′ or 5′-CTGTGCTTTACTGCGCGCTC-3′
for human NUAK2.
For NUAK2 A236T knock-in cell line generation, the guide sequence used is 5′-
GTGCAGGATTGAGTCAAACAC-3′ and the ssODN sequence used is 5′-TGG
GTTTCCCCAGGGTCTGGAGAAGGGCGGGCCAAGAGCTGAAGAAAAAC
CCAGGCCTTGACATGACCTGTGACCGTGTTTGACTCAATCCTGCAGATTA
CCGACTTCGGTCTCTCCAACCTCTACCATCAAGGCAAGTTCCTGCAGACA
TTCTGTGGGAGCCCCCTCTATGCCTCGCCAGAGATTGTCAATGGGAAG
CC-3’.
AAV-sgRNA-Cre plasmid is modified from AAV:ITR-U6-sgRNA(backbone)-
pCBh-Cre-WPRE-hGHpA-ITR plasmid which was a gift from Feng Zhang
(Addgene #60229)40. The guide sequence used are listed below
Non-targeting, 5′-ATGTTGCAGTTCGGCTCGAT-3′ and 5′-
ACGTGTAAGGCGAACGCCTT-3′, mouse Nuak2, 5′-
ATGGTGCGGGGACCGCGAGG-3′ and 5′-CTACGAGTTCCTGGAGACGC-3′,
human YAP, 5′-CGACTCCTTCTTCAAGCCGC-3′ and 5′-
GCCGGTTGCCCGGGTCCGGA-3′.
NUAK2 and YAP gene expression analysis. We downloaded gene expression
data of previous study71 from GEO database (GES14520). Then, NUAK2 and YAP
expression of all liver tumor samples were extracted to perform Spearman corre-
lation analysis. Correlation coefficient and p-value were reported. To compare the
gene expression level in tumor versus normal tissues, we used paired Wilcoxon test
to compare the matched tumor-normal gene expression data of YAP and NUAK2.
Statistical analysis. The two-tailed, Student’s t test was used to compare between
two groups and expressed as P values. *P < 0.05, **P < 0.01, ***P < 0.001.
Data availability
The Gene Expression Omnibus accession number is [GSE107860]. Additional data
supporting the findings of this study are available from the authors on request.
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